Neostigmine

7 min read Last updated April 8, 2026

How to use in theatre (practical approach)

  • Confirm appropriate depth of block before giving reversal
    • Aim for TOF count 4 with fade (or better); ideally TOF ratio improving and/or clinical signs returning
    • Neostigmine has a ceiling effect—ineffective for profound block (e.g. PTC only)
  • Dose neostigmine and antimuscarinic together
    • Typical adult dose: 0.04–0.07 mg/kg IV (max commonly 5 mg); titrate to monitoring and clinical context
    • Give with glycopyrrolate 0.01 mg/kg IV (or atropine 0.02 mg/kg IV) to mitigate muscarinic effects
  • Timing and expectations
    • Onset within minutes; peak effect ~7–10 min; duration ~30–60+ min (variable)
    • Extubation target: TOF ratio ≥0.9 plus satisfactory clinical recovery
  • If inadequate reversal
    • Check: residual anaesthetic/opioid, hypothermia, electrolyte disturbance (Mg2+), acidosis, NMBD dosing/agent, monitoring site, equipment
    • Avoid repeated large neostigmine doses once near full recovery (risk paradoxical weakness/cholinergic effects); support ventilation and reassess

When to avoid / be cautious

  • Bradyarrhythmias and conduction disease
    • Always co-administer antimuscarinic; be prepared to treat severe bradycardia/asystole (rare but reported)
  • Asthma/COPD and bronchospasm risk
    • Muscarinic bronchoconstriction and secretions; glycopyrrolate preferred over atropine for less tachycardia/central effects
  • Bowel/urinary obstruction
    • Cholinergic stimulation may worsen obstruction; consider alternatives/supportive strategy depending on urgency
  • Myasthenia gravis and other neuromuscular disorders
    • Response to NMBDs and reversal is unpredictable; use quantitative monitoring and careful titration; consider sugammadex if aminosteroid NMBD used

Classification and key role

  • Reversible acetylcholinesterase inhibitor (carbamate) used to reverse non-depolarising neuromuscular blockade
  • Quaternary ammonium compound → poorly lipid soluble → minimal CNS penetration

Mechanism of action (NMJ and autonomic)

  • Inhibits acetylcholinesterase by carbamylation → increases ACh concentration at nicotinic receptors at NMJ → competitively displaces non-depolarising NMBD
  • Also increases ACh at muscarinic receptors → bradycardia, bronchoconstriction, secretions, GI motility, miosis
  • Ceiling effect: once AChE maximally inhibited, further dose does not increase reversal; excess ACh may impair neuromuscular transmission (depolarising-like weakness)

Pharmacokinetics

  • Route: IV for reversal (also IM/SC/oral in other indications)
  • Onset: ~1–3 min; peak: ~7–10 min; duration: ~30–60+ min (context dependent)
  • Distribution: low lipid solubility; limited CNS entry; crosses placenta to some extent (clinical relevance usually limited)
  • Elimination: renal excretion significant; some hepatic metabolism; prolonged effect in renal impairment

Dose and co-administration

  • Neostigmine 0.04–0.07 mg/kg IV (often 2.5–5 mg adult) depending on depth of block and agent used
  • Glycopyrrolate 0.01 mg/kg IV (typical adult 0.4–0.8 mg) given with neostigmine; commonly mixed in same syringe
  • Atropine 0.02 mg/kg IV is an alternative antimuscarinic (more tachycardia, crosses BBB)
  • Avoid giving antimuscarinic long before neostigmine (risk unopposed muscarinic effects when neostigmine peaks) and avoid neostigmine without antimuscarinic

Effects (system by system)

  • Cardiovascular: bradycardia, AV block, hypotension; rarely severe bradycardia/asystole (especially with high vagal tone, opioids, beta-blockers, conduction disease)
  • Respiratory: bronchoconstriction, increased secretions; may worsen reactive airway disease
  • GI/GU: increased peristalsis, cramps, diarrhoea; increased salivation; urinary urgency
  • Eye: miosis, lacrimation
  • NMJ: improves transmission in presence of non-depolarising block; excessive ACh can cause weakness/fasciculations (cholinergic excess)

Interactions and special situations

  • Profound block: neostigmine unreliable; consider waiting for spontaneous recovery or use sugammadex if rocuronium/vecuronium used
  • Volatile agents potentiate NMBDs → may delay recovery; ensure adequate time and monitoring before reversal
  • Aminoglycosides, magnesium, lithium can potentiate block and impair reversal
  • Suxamethonium: anticholinesterases can prolong phase I block by inhibiting plasma cholinesterase; may antagonise phase II block—clinically avoid routine use for sux reversal
  • Renal impairment: prolonged neostigmine effect and muscarinic side effects; dose carefully and use quantitative monitoring

Adverse effects and management

  • Cholinergic effects: bradycardia, bronchospasm, secretions, nausea/vomiting, abdominal cramps
  • Treat severe muscarinic effects with antimuscarinic (glycopyrrolate/atropine) and supportive care (oxygen, bronchodilators, fluids/vasopressors as needed)
  • Cholinergic crisis (rare perioperatively): weakness + muscarinic signs; manage with airway/ventilation, atropine for muscarinic symptoms, and stop further anticholinesterase

Comparison: neostigmine vs sugammadex (high-yield)

  • Neostigmine: indirect reversal; requires some recovery; ceiling effect; muscarinic side effects; inexpensive
  • Sugammadex: encapsulates rocuronium/vecuronium; can reverse deep block rapidly; fewer cholinergic effects; cost and anaphylaxis considerations
Describe the mechanism by which neostigmine reverses non-depolarising neuromuscular blockade.

Key points expected: site of action, enzyme interaction, effect on ACh, and why it only works when some recovery has occurred.

  • Neostigmine is a reversible acetylcholinesterase inhibitor (carbamate) → carbamylates AChE and inhibits breakdown of acetylcholine
  • Increased ACh at the NMJ increases competition at nicotinic receptors → displaces non-depolarising NMBD from receptors
  • Requires partial spontaneous recovery: if too many receptors are occupied (deep block), increased ACh cannot restore transmission effectively
  • Also increases ACh at muscarinic receptors → necessitates co-administration of an antimuscarinic
Why must neostigmine be given with an antimuscarinic? Compare glycopyrrolate and atropine.

Examiners look for muscarinic side effects, timing, and drug properties (quaternary vs tertiary).

  • Neostigmine increases ACh at muscarinic receptors → bradycardia/AV block, bronchospasm, secretions, increased GI motility, miosis
  • Glycopyrrolate: quaternary ammonium → minimal CNS penetration; less tachycardia; good antisialagogue; commonly paired with neostigmine
  • Atropine: tertiary amine → crosses BBB; more tachycardia; may be preferred in profound bradycardia but can cause central effects (especially in children/elderly)
  • Give together to match onset and avoid periods of unopposed muscarinic activity
What is meant by the 'ceiling effect' of neostigmine and what are the clinical implications?

This is commonly examined around residual paralysis and inappropriate redosing.

  • AChE becomes maximally inhibited at clinically used doses; further neostigmine does not meaningfully increase ACh at NMJ
  • Therefore neostigmine cannot reliably reverse deep block (e.g. PTC only); must wait for recovery or use sugammadex (if appropriate NMBD)
  • Excess ACh can worsen neuromuscular transmission (depolarising-like effect) and increase muscarinic adverse effects
Give a typical dosing regimen for neostigmine and glycopyrrolate for reversal in an adult and explain how you would titrate it.

Expect dose ranges, maximum dose, and titration to quantitative monitoring.

  • Neostigmine 0.04–0.07 mg/kg IV (often 2.5–5 mg total adult); glycopyrrolate 0.01 mg/kg IV (often 0.4–0.8 mg)
  • Titrate to depth of block: smaller dose if TOF ratio already near 0.9; larger dose if TOF count 4 with clear fade
  • Avoid routine full-dose neostigmine when already recovered (risk cholinergic effects and paradoxical weakness)
A patient has TOF count 1 at the adductor pollicis at the end of surgery. Is neostigmine appropriate? What would you do?

This tests understanding of depth of block and limitations of neostigmine.

  • TOF count 1 indicates relatively deep block; neostigmine may be slow/unreliable and may not achieve timely TOF ≥0.9
  • Options: wait for further spontaneous recovery (optimize temperature, acid-base, electrolytes) then give neostigmine when TOF count improves
  • If rocuronium/vecuronium used and rapid reversal needed, consider sugammadex according to depth of block and local guidance
  • Continue ventilation/anaesthesia until objective recovery achieved
Explain why giving neostigmine after full recovery from neuromuscular block can cause weakness.

Often asked as a concept question about 'paradoxical weakness'.

  • With minimal NMBD present, excess ACh from AChE inhibition can desensitise nicotinic receptors and produce a depolarising-like block
  • Additionally, muscarinic effects (bronchospasm/secretions) can mimic poor recovery clinically
  • Hence use quantitative monitoring and avoid unnecessary neostigmine when TOF ratio already ≥0.9
List the main adverse effects of neostigmine and how you would manage severe bradycardia after administration.

Expect system-based list and immediate management steps.

  • Adverse effects: bradycardia/AV block, hypotension, bronchospasm, increased secretions, nausea/vomiting, abdominal cramps/diarrhoea, miosis
  • Management of severe bradycardia: oxygen, check pulse/ECG, stop surgical vagal stimulus, give atropine IV (or additional glycopyrrolate), consider adrenaline if refractory, support circulation
  • Consider contributing factors: high vagal tone, opioids, beta-blockade, hypoxia, conduction disease
How does neostigmine interact with suxamethonium? Would you use it to reverse suxamethonium?

This is a classic FRCA pharmacology viva topic.

  • Anticholinesterases inhibit plasma cholinesterase → can prolong suxamethonium metabolism and therefore prolong phase I block
  • In phase II block, anticholinesterases may antagonise block, but this is unpredictable and not routine practice
  • Therefore neostigmine is not used to reverse typical suxamethonium block; manage with ventilation/sedation until recovery
Outline factors that may cause failure of reversal after neostigmine despite apparently adequate dosing.

This tests differential diagnosis of residual paralysis and perioperative physiology.

  • Given too early (deep block) → ceiling effect and inadequate reversal
  • Potentiation of NMBD: volatile anaesthetics, aminoglycosides, magnesium, lithium
  • Physiology: hypothermia, acidosis, electrolyte disturbance (hypocalcaemia, hypermagnesaemia), poor perfusion
  • Monitoring issues: wrong site, poor calibration, movement artefact; clinical signs unreliable without quantitative monitoring
  • Non-NMBA causes of weakness: residual anaesthetic/opioid, hypoglycaemia, stroke, myopathy, myasthenic syndromes
Explain why quantitative neuromuscular monitoring is recommended when using neostigmine.

Often linked to awareness of residual paralysis and TOF ratio targets.

  • Clinical tests and qualitative fade detection are insensitive for residual block; significant weakness can persist with TOF ratio 0.4–0.9
  • Extubation should target TOF ratio ≥0.9 to reduce airway obstruction, hypoxia, aspiration risk and postoperative pulmonary complications
  • Quantitative monitoring guides appropriate timing/dose and avoids unnecessary neostigmine when already recovered

0 comments